CancerGD: A Resource for Identifying and Interpreting Genetic Dependencies in Cancer

Ashworth, 2011, Genetic interactions in cancer progression and treatment, Cell, 145, 30, 10.1016/j.cell.2011.03.020 Barretina, 2012, The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity, Nature, 483, 603, 10.1038/nature11003 Basu, 2013, An interactive resource to identify cancer genetic and lineage dependencies targeted by small molecules, Cell, 154, 1151, 10.1016/j.cell.2013.08.003 Brough, 2011, Searching for synthetic lethality in cancer, Curr. Opin. Genet. Dev., 21, 34, 10.1016/j.gde.2010.10.009 Brough, 2011, Functional viability profiles of breast cancer, Cancer Discov., 1, 260, 10.1158/2159-8290.CD-11-0107 Campbell, 2016, Large-scale profiling of kinase dependencies in cancer cell lines, Cell Rep., 14, 2490, 10.1016/j.celrep.2016.02.023 Cheung, 2011, Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer, Proc. Natl. Acad. Sci. USA, 108, 12372, 10.1073/pnas.1109363108 Cowley, 2014, Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies, Sci. Data, 1, 140035, 10.1038/sdata.2014.35 Daemen, 2013, Modeling precision treatment of breast cancer, Genome Biol., 14, R110, 10.1186/gb-2013-14-10-r110 Downward, 2015, RAS synthetic lethal screens revisited: still seeking the elusive prize?, Clin. Cancer Res., 21, 1802, 10.1158/1078-0432.CCR-14-2180 Forbes, 2015, COSMIC: exploring the world's knowledge of somatic mutations in human cancer, Nucleic Acids Res., 43, D805, 10.1093/nar/gku1075 Garnett, 2012, Systematic identification of genomic markers of drug sensitivity in cancer cells, Nature, 483, 570, 10.1038/nature11005 Gray, 2015, Genenames.org: the HGNC resources in 2015, Nucleic Acids Res., 43, D1079, 10.1093/nar/gku1071 Griffith, 2013, DGIdb: mining the druggable genome, Nat. Methods, 10, 1209, 10.1038/nmeth.2689 Helming, 2014, ARID1B is a specific vulnerability in ARID1A-mutant cancers, Nat. Med., 20, 251, 10.1038/nm.3480 Hsu, 2015, The spliceosome is a therapeutic vulnerability in MYC-driven cancer, Nature, 525, 384, 10.1038/nature14985 Hynes, 2005, ERBB receptors and cancer: the complexity of targeted inhibitors, Nat. Rev. Cancer, 5, 341, 10.1038/nrc1609 Iorio, 2016, A landscape of pharmacogenomic interactions in cancer, Cell, 166, 740, 10.1016/j.cell.2016.06.017 Jackson, 2010, Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application, Nat. Rev. Drug Discov., 9, 57, 10.1038/nrd3010 Kaelin, 2012, Molecular biology. Use and abuse of RNAi to study mammalian gene function, Science, 337, 421, 10.1126/science.1225787 Kelley, 2005, Systematic interpretation of genetic interactions using protein networks, Nat. Biotechnol., 23, 561, 10.1038/nbt1096 Lord, 2015, Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors, Annu. Rev. Med., 66, 455, 10.1146/annurev-med-050913-022545 Luo, 2009, Principles of cancer therapy: oncogene and non-oncogene addiction, Cell, 136, 823, 10.1016/j.cell.2009.02.024 Marcotte, 2012, Essential gene profiles in breast, pancreatic, and ovarian cancer cells, Cancer Discov., 2, 172, 10.1158/2159-8290.CD-11-0224 Marcotte, 2016, Functional genomic landscape of human breast cancer drivers, vulnerabilities, and resistance, Cell, 164, 293, 10.1016/j.cell.2015.11.062 Shao, 2013, ATARiS: computational quantification of gene suppression phenotypes from multisample RNAi screens, Genome Res., 23, 665, 10.1101/gr.143586.112 Szklarczyk, 2015, STRING v10: protein-protein interaction networks, integrated over the tree of life, Nucleic Acids Res., 43, D447, 10.1093/nar/gku1003 Vogelstein, 2013, Cancer genome landscapes, Science, 339, 1546, 10.1126/science.1235122 Wagner, 2016, DGIdb 2.0: mining clinically relevant drug-gene interactions, Nucleic Acids Res., 44, D1036, 10.1093/nar/gkv1165 Wang, 2017, Gene essentiality profiling reveals gene networks and synthetic lethal interactions with oncogenic Ras, Cell, 168, 890, 10.1016/j.cell.2017.01.013 Yang, 2013, Genomics of Drug Sensitivity in Cancer (GDSC): a resource for therapeutic biomarker discovery in cancer cells, Nucleic Acids Res., 41, D955, 10.1093/nar/gks1111